Author

M. E. Cilento

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

P. R. Tedbury· 3 shared S. G. Sarafianos· 3 shared H. Zhang· 2 shared R. L. Slack· 2 shared S. Lan· 2 shared W. A. Cantara· 2 shared A. Emanuelli Castaner· 1 shared E. A. Boggs· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

P. R. Tedbury

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies

S. Lan, G. Neilsen, R. L. Slack, W. A. Cantara, A. Emanuelli Castaner, Z. C. Lorson, N. D. Lulkin, H. Zhang, J. Lee, M. E. Cilento, P. R. Tedbury, S. G. Sarafianos

This study identifies E166V as a key mutation conferring high nirmatrelvir resistance in SARS-CoV-2, with differential effects on Omicron and WA1 variants, and explores strategies to overcome resistance.

bioRxiv · Dec 31, 2022 · PreprintMicrobiology

Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication

S. Lan, P. R. Tedbury, Y. T. Ong, R. Shah, R. L. Slack, M. E. Cilento, H. Zhang, H. Du, N. Lulkin, U. Q. Le, K. A. Kirby, I. Melcak, W. A. Cantara, E. A. Boggs, S. G. Sarafianos

This paper develops SARS-CoV-2 replicon systems and cell lines for antiviral screening and mechanistic studies, enabling research at lower biosafety levels.

bioRxiv · Dec 29, 2021 · PreprintMicrobiology

Development of Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) by Wild-Type and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1

M. E. Cilento, E. Michailidis, T. V. Ilina, E. Nagy, H. Mitsuya, M. Parniak, P. R. Tedbury, S. G. Sarafianos

This study identifies mutations conferring resistance to EFdA in HIV-1, showing M184V as the primary determinant and A114S enhancing resistance.

bioRxiv · Sep 4, 2020Microbiology